Skip to main content
Premium Trial:

Request an Annual Quote

Bionano Laboratories OGM-Dx HemeOne Test

Bionano Laboratories, a subsidiary of Bionano Genomics, has launched OGM-Dx HemeOne, a laboratory-developed test based on optical genome mapping (OGM). The assay analyzes blood or bone marrow samples to detect structural variants (SVs) of diagnostic and prognostic utility in individuals with a new or an existing diagnosis of a hematological malignancy. According to Bionano, the reports from OGM-Dx HemeOne will include a targeted analysis of guidelines-based, disease-specific SVs, and a whole-genome analysis for the detection of recurrent and novel biomarkers associated with various hematological malignancy indications.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.